SpringWorks Therapeutics (SWTX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

SWTX SpringWorks Therapeutics

Watchlist

57.760
+4.350+8.14%

Close Feb 28 16:00 ET

57.950
+0.190+0.33%

Post 20:01 ET

4.33BMarket Cap-16.60P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

10 Health Care Stocks Whale Activity In Today's Session
BenzingaFeb 27 12:35 ET
J.P. Morgan Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Announces Target Price $70
Moomoo NewsFeb 25 06:31 ET · Ratings
J.P. Morgan Sticks to Its Buy Rating for Springworks Therapeutics (SWTX)
TipRanksFeb 25 06:18 ET · Ratings
SpringWorks Therapeutics Insider Sold Shares Worth $2,866,534, According to a Recent SEC Filing
MT NewswiresFeb 25 03:34 ET
Assessing SpringWorks Therapeutics: Insights From 6 Financial Analysts
BenzingaFeb 24 09:01 ET
Why SpringWorks Therapeutics, Inc. (SWTX) Is the Best Performing Pharma Stock So Far in 2025
Yahoo FinanceFeb 23 15:17 ET

Comments

Teddy123

Feb 20 05:32

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

$SpringWorks Therapeutics (SWTX.US)$
Can SpringWorks' Dual Drug Strategy Transform Its Financial Future? Q4 Results Reveal Key Insights

Teddy123

Feb 12 04:44

UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

$SpringWorks Therapeutics (SWTX.US)$
Historic FDA Approval: Groundbreaking NF1-PN Treatment Shows Remarkable 52% Response in Children

Teddy123

Feb 11 17:56

SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

$SpringWorks Therapeutics (SWTX.US)$
Breakthrough FDA Approval: New Drug Shows Remarkable 52% Response Rate in Children with Rare Tumor Disease

Trytosaveabit

Feb 11 14:46

News

$SpringWorks Therapeutics (SWTX.US)$ Reuters· 2 mins ago
FDA: Approved Mirdametinib, for Adult & Pediatric Patients 2 Years of Age & Older With Nf1 Who Have Symptomatic Pn Not Amenable to Complete Resection

Kishen bossku

Feb 10 12:30

$SpringWorks Therapeutics (SWTX.US)$ wonderful 😊

SWTX SpringWorks Therapeutics

Trade Overview

Capital Trend

News

Comments

Trending Stocks